DYNACIRC
LOE ApproachingNDAORALCAPSULE
Approved
Dec 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DYNACIRC is an oral small-molecule capsule approved by GSK in December 1990 for an unspecified indication. The mechanism of action and pharmacologic class are not documented in available data. Patient population and therapeutic use cannot be determined from current records.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); team likely focused on transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings and LOE-approaching status signal limited career growth or expansion opportunities on this product. Professionals assigned here are typically managing mature-to-declining revenues and preparing for generic transition.
Brand ManagerField Sales Representative
Worked on DYNACIRC at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.